ACCUSTEM SCIENCES, INC.

ACUT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item Jun 2023 May 2023 Mar 2023 Feb 2023 Dec 2022 Nov 2022 Sep 2022 Aug 2022
Revenue
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $14.6K $15.6K $58.3K
SG&A Expense $358.2K $817.7K $840.9K
Operating Income $-372.8K $-833.3K $-899.1K
Operating Margin
Interest Expense
Pretax Income $-372.8K $-833.3K $-899.1K
Income Tax Expense
Net Income $-372.8K $-833.3K $-899.1K
Net Margin
EPS (Basic) $-0.03 $-0.07 $-0.08
EPS (Diluted) $-0.03 $-0.07 $-0.08
Shares Outstanding (Basic) 11.3M 11.3M 11.3M 11.3M 11.3M 11.3M 11.3M 11.3M
Shares Outstanding (Diluted) 11.3M 11.3M 11.3M 11.3M 11.3M 11.3M 11.3M 11.3M
Dividends Per Share
← Newer Page 4 of 5 Older →